Cardio Diagnostics Holdings Stock Today
| CDIOW Stock | USD 0.03 0 16.14% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Cardio Diagnostics is selling for under 0.0295 as of the 13th of April 2025; that is 16.14 percent increase since the beginning of the trading day. The stock's lowest day price was 0.0287. Cardio Diagnostics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 13th of January 2025 and ending today, the 13th of April 2025. Click here to learn more.
Cardio Diagnostics Inc. develops and manufactures a genetic and epigenetic based test for prevention and detection of cardiovascular disease. Cardio Diagnostics Inc. was founded in 2017 and is based in Chicago, Illinois. Cardio Diagnostics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.. More on Cardio Diagnostics Holdings
Moving together with Cardio Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Cardio Stock Highlights
| CEO CoFounder | Meeshanthini Dogan |
| Thematic Idea | Pharmaceutical Products (View all Themes) |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
Cardio Diagnostics Holdings (CDIOW) is traded on NASDAQ Exchange in USA. It is located in 311 West Superior Street, Chicago, IL, United States, 60654 and employs 13 people. Cardio Diagnostics is listed under Biotechnology category by Fama And French industry classification. The company classifies itself under Biotechnology sector and is part of Health Care industry.
Cardio Diagnostics generates negative cash flow from operations
Check Cardio Diagnostics Probability Of Bankruptcy
Cardio Diagnostics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Cardio Diagnostics market risk premium is the additional return an investor will receive from holding Cardio Diagnostics long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0173 | |||
| Jensen Alpha | 0.0197 | |||
| Total Risk Alpha | 0.9697 | |||
| Sortino Ratio | 0.0113 |
Cardio Stock Against Markets
Cardio Diagnostics Corporate Management
| Esq JD | Chief Officer | Profile | |
| Timur Dogan | Chief Officer | Profile | |
| Khullani JD | Vice Strategy | Profile | |
| MBA JD | CFO Director | Profile | |
| Khullani Abdullah | VP Strategy | Profile |
Additional Tools for Cardio Stock Analysis
When running Cardio Diagnostics' price analysis, check to measure Cardio Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardio Diagnostics is operating at the current time. Most of Cardio Diagnostics' value examination focuses on studying past and present price action to predict the probability of Cardio Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardio Diagnostics' price. Additionally, you may evaluate how the addition of Cardio Diagnostics to your portfolios can decrease your overall portfolio volatility.